Citadel Advisors’s Vera Therapeutics VERA Stock Holding History
Bought
Maintained
Sold
Other funds holding VERA
ACA
DTC
DM
KCM
SI
Citadel Advisors's VERA Position: Q2 2026 in Review
Citadel Advisors sold out of Vera Therapeutics (VERA) in Q2 2026, closing a stake of 429,761 shares — an estimated $16M sold.
Citadel Advisors first reported a position in VERA in Q2 2021 and held it in 19 quarters. The position peaked at $49.1M in Q1 2022. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.
- Citadel Advisors reported no remaining Vera Therapeutics position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 429,761 Vera Therapeutics shares in Q2 2026, an estimated $16M.
- Citadel Advisors first reported a position in Vera Therapeutics in Q2 2021 and held it in 19 quarters.
- Citadel Advisors's Vera Therapeutics position peaked at $49.1M in Q1 2022.
- 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.